Positron, through its wholly owned subsidiary, Manhattan Isotope Technology (MIT), has executed a memorandum of understanding with the Institute of Nuclear Research (INR) of Troitsk, Russia. MIT and INR will collaborate on strontium-82 (Sr-82) production beginning with a pharmaceutical ingredient validation exercise in 2012.
A goal of the collaboration is to increase the annual production capability of Sr-82 produced at INR and thereafter increase supply to varied markets, according to the Fishers, Ind.-based Positron.
Initial shipments of Sr-82 samples are expected at the MIT Facility in Lubbock, Texas, in the spring of 2012. These samples will be processed at MIT for final purification into an active pharmaceutical ingredient. This supply source and radiochemical methodology work will be a part of the 2012 Drug Master File submission to the FDA. Since 1997, INR at Troitsk has made contributions to the yearly supply of Sr-82 in the U.S. through the supply of target material to Los Alamos National Laboratory for processing.
Additional Russian institutions participating in the Sr-82 project are the Institute of Physics and Power Engineering and The Isotope Company, both of which are located in the Russian city of Obninsk.